High-level expression of a novel epitope of CD59 identifies a subset of CD34+ bone marrow cells highly enriched for pluripotent stem cells.
To further define the hierarchy of human hematopoietic progenitor cells, we have attempted to identify antibodies to cell-surface molecules expressed on CD34+ progenitor cell subsets. Herein we describe the utility of a new monoclonal antibody, HCC-1, which binds to a novel epitope of CD59 differentially expressed among CD34+ progenitor cells. HCC-1 subdivides the adult marrow CD34+ population into HCC-1high and HCC-1low/- fractions of approximately equal size. Cobblestone area-forming cells (CAFC) in long-term bone marrow culture were enriched 10-30-fold in CD34+HCC-1high cells compared with CD34+HCC1-low/- cells and two-fold compared with CD34+ cells. When injected into fetal human bone fragments implanted in SCID mice, the CD34+HCC-1high population showed potent engrafting activity leading to the production of myeloid, lymphoid, and erythroid elements, as well as the retention of progenitor cell phenotype. These studies demonstrate that the CD34+HCC-1high population contains primitive pluripotent hematopoietic stem cells. No hematopoietic engrafting activity was detected in the CD34+HCC-1low/- population. Consistent with this finding, simultaneous five-color flow cytometric analysis revealed that HCC-1high cells include virtually all CD34+Thy-1+Lin- cells, a cell population previously characterized as highly enriched for primitive pluripotent hematopoietic stem cells. The ability of CD34+ cells divided into subsets by HCC-1 to produce T cells was assessed by transplantation of sorted cells into human fetal thymus implanted into SCID mice. A higher frequency of thymus-engrafting activity was observed in the CD34+HCC-1high than in the CD34+HCC-1low/- population. Consistent with the limited ability to engraft in the SCID-hu thymus model, the CD34+HCC-1low/- population was shown to contain a low frequency of CD34+CD10+ lymphoid progenitor cells. We conclude that the HCC-1 epitope is expressed at high levels on a subset of CD34+ cells that contain virtually all primitive pluripotent hematopoietic stem cells and that the population of CD59 molecules expressed on CD34+ cells is not homogeneous.
Hill
B
B
SyStemix, Palo Alto, CA 94304, USA.
Rozler
E
E
Travis
M
M
Chen
S
S
Zannetino
A
A
Simmons
P
P
Galy
A
A
Chen
B
B
Hoffman
R
R
D000818:Animals; D018952:Antigens, CD34 / Q000032:analysis* / Q000096:biosynthesis; D001798:Blood Proteins / Q000032:analysis; D001854:Bone Marrow Cells; D016025:Bone Transplantation / Q000276:immunology; D002478:Cells, Cultured; D018925:Chemokines / Q000032:analysis / Q000096:biosynthesis; D019742:Chemokines, CC; D046508:Culture Techniques; D000939:Epitopes / Q000032:analysis; D016332:Fetal Tissue Transplantation / Q000276:immunology; D005434:Flow Cytometry; D015870:Gene Expression; D006412:Hematopoietic Stem Cells / Q000166:cytology*; D006801:Humans; D007700:Kinetics; D051379:Mice; D016513:Mice, SCID; D015260:Neprilysin / Q000032:analysis / Q000096:biosynthesis; D013997:Time Factors; D014183:Transplantation, Heterologous / Q000276:immunology
D018952:Antigens, CD34; D001798:Blood Proteins; C097720:CCL14 protein, human; D018925:Chemokines; D019742:Chemokines, CC; D000939:Epitopes; D015260:Neprilysin